Clinical Trial Update: Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma

View source ↗

Summary

This document describes an Expanded Access Protocol to provide Bortezomib to multiple myeloma patients who have received at least two prior therapies and are re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Multiple Myeloma | Status: COMPLETED